Constitutive excitation by Gly90Asp rhodopsin rescues rods from degeneration caused by elevated production of cGMP in the dark.
Previous experiments indicate that congenital human retinal degeneration caused by genetic mutations that change the Ca(2+) sensitivity of retinal guanylyl cyclase (retGC) can result from an increase in concentration of free intracellular cGMP and Ca(2+) in the photoreceptors. To rescue degeneration in transgenic mouse models having either the Y99C or E155G mutations of the retGC modulator guanylyl cyclase-activating protein 1 (GCAP-1), which produce elevated cGMP synthesis in the dark, we used the G90D rhodopsin mutation, which produces constitutive stimulation of cGMP hydrolysis. The effects of the G90D transgene were evaluated by measuring retGC activity biochemically, by recording single rod and electroretinogram (ERG) responses, by intracellular free Ca(2+) measurement, and by retinal morphological analysis. Although the G90D rhodopsin did not alter the abnormal Ca(2+) sensitivity of retGC in the double-mutant animals, the intracellular free cGMP and Ca(2+) concentrations returned close to normal levels, consistent with constitutive activation of the phosphodiesterase PDE6 cascade in darkness. G90D decreased the light sensitivity of rods but spared them from severe retinal degeneration in Y99C and E155G GCAP-1 mice. More than half of the photoreceptors remained alive, appeared morphologically normal, and produced electrical responses, at the time when their siblings lacking the G90D rhodopsin transgene lost the entire retinal outer nuclear layer and no longer responded to illumination. These experiments indicate that mutations that lead to increases in cGMP and Ca(2+) can trigger photoreceptor degeneration but that constitutive activation of the transduction cascade in these animals can greatly enhance cell survival.
Woodruff
Michael L
ML
Department of Physiological Science, University of California, Los Angeles, Los Angeles, California 90095, USA.
Olshevskaya
Elena V
EV
Savchenko
Andrey B
AB
Peshenko
Igor V
IV
Barrett
Ronald
R
Bush
Ronald A
RA
Sieving
Paul A
PA
Fain
Gordon L
GL
Dizhoor
Alexander M
AM
D000221:Adaptation, Ocular / Q000235:genetics; D000818:Animals; D001224:Aspartic Acid / Q000235:genetics*; D002118:Calcium / Q000378:metabolism; D006152:Cyclic GMP / Q000235:genetics / Q000378:metabolism*; D003545:Cysteine / Q000235:genetics; D003623:Dark Adaptation / Q000235:genetics / Q000502:physiology; D004195:Disease Models, Animal; D004596:Electroretinography / Q000379:methods; D005786:Gene Expression Regulation / Q000528:radiation effects; D005998:Glycine / Q000235:genetics*; D051604:Guanylate Cyclase-Activating Proteins / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008822:Mice, Transgenic; D046529:Microscopy, Electron, Transmission / Q000379:methods; D010812:Physical Stimulation / Q000379:methods; D012160:Retina / Q000473:pathology / Q000503:physiopathology; D012162:Retinal Degeneration / Q000235:genetics / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D017948:Retinal Rod Photoreceptor Cells / Q000503:physiopathology* / Q000648:ultrastructure; D012243:Rhodopsin / Q000235:genetics / Q000502:physiology*; D014443:Tyrosine / Q000235:genetics
D051604:Guanylate Cyclase-Activating Proteins; C496737:Guca1a protein, mouse; D001224:Aspartic Acid; D014443:Tyrosine; D012243:Rhodopsin; D006152:Cyclic GMP; D003545:Cysteine; D002118:Calcium; D005998:Glycine
Bioessays. 2000 Apr;22(4):337-50
10723031
Methods Enzymol. 2000;315:708-17
10736735
J Biol Chem. 2000 Apr 21;275(16):12175-84
10766853
Hum Mol Genet. 2000 Dec 12;9(20):3065-73
11115851
Physiol Rev. 2001 Jan;81(1):117-151
11152756
J Biol Chem. 1998 Jul 10;273(28):17311-4
9651312
Mol Cell. 1998 Jul;2(1):129-33
9702199
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9039-44
10430891
Vision Res. 2004 Dec;44(28):3235-51
15535992
Graefes Arch Clin Exp Ophthalmol. 2005 Mar;243(3):235-42
15452722
J Physiol. 2005 Oct 1;568(Pt 1):83-95
15994181
Neuron. 2005 Nov 3;48(3):387-401
16269358
Invest Ophthalmol Vis Sci. 2006 May;47(5):2185-94
16639031
J Neurosci. 2006 Apr 26;26(17):4472-80
16641226
J Biol Chem. 2006 Aug 18;281(33):23830-41
16793776
Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1124-32
15790869
Nature. 2001 May 3;411(6833):90-4
11333983
J Biol Chem. 2001 Jul 13;276(28):26218-29
11306565
J Neurosci. 2001 Aug 1;21(15):5449-60
11466416
Am J Hum Genet. 2001 Sep;69(3):471-80
11484154
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9948-53
11493703
Vision Res. 2002 Feb;42(4):401-15
11853756
Mol Cell Biochem. 2002 Jan;230(1-2):139-47
11952089
Neuron. 2002 May 30;34(5):773-85
12062023
J Physiol. 2002 Aug 1;542(Pt 3):843-54
12154183
Neuron. 2002 Sep 26;36(1):81-91
12367508
Adv Exp Med Biol. 2002;514:411-38
12596936
Nat Neurosci. 2003 Jul;6(7):731-5
12778053
Nat Genet. 2003 Oct;35(2):158-64
14517541
J Physiol. 2003 Nov 1;552(Pt 3):763-76
12949220
J Biol Chem. 2004 Apr 23;279(17):16903-6
14993224
J Gen Physiol. 2004 Jun;123(6):729-41
15173221
J Neurosci. 2004 Jul 7;24(27):6078-85
15240799
Biochemistry. 2004 Nov 2;43(43):13796-804
15504042
Invest Ophthalmol Vis Sci. 2004 Nov;45(11):3863-70
15505030
J Physiol. 1979 Mar;288:589-611
112242
J Gen Physiol. 1979 Sep;74(3):415-26
225407
Biophys Struct Mech. 1981;7(3):125-30
6268219
Nature. 1984 Oct 18-24;311(5987):661-3
6434995
J Physiol. 1987 Oct;391:347-70
2451008
Nature. 1988 Jul 7;334(6177):64-6
2455233
Annu Rev Neurosci. 1989;12:289-327
2467600
Proc Natl Acad Sci U S A. 1989 Jun;86(11):4311-5
2542968
Methods Enzymol. 1989;172:230-62
2747529
Anal Biochem. 1991 Feb 15;193(1):61-71
1904204
Anal Biochem. 1992 Feb 14;201(1):119-26
1621949
Biochim Biophys Acta. 1993 Mar 1;1141(2-3):111-49
8382952
Nature. 1994 Feb 17;367(6464):639-42
8107847
Exp Eye Res. 1994 May;58(5):631-5
7925701
Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):880-4
7846071
J Gen Physiol. 1995 Nov;106(5):863-90
8648296
Nat Genet. 1997 Feb;15(2):216-9
9020854
J Biol Chem. 1997 May 30;272(22):14327-33
9162068
Biosci Rep. 1997 Oct;17(5):429-73
9419388
Hum Mol Genet. 1998 Feb;7(2):273-7
9425234
Hum Mol Genet. 1998 Jul;7(7):1179-84
9618177